Back

Outcomes, resource utilization and predictors of thirty day readmission in patients with heart failure with preserved ejection fraction (HFpEF): Insights from the Nationwide Readmissions Database 2017

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Changing Epidemiology of Heart Failure Diastolic Ventricular Dysfunction ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Anil Jha

Lawrence General Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Chronic obstructive pulmonary disease in heart failure: influence on circulating biomarkers and outcome
Doctor G. Vergaro (Pisa, IT)
Abstract Slides
Presentation thumbnail
Importance of familial predisposition to heart failure to the risk of anthracycline related cardiotoxicity: a nationwide study
Doctor A. Banke (Odense, DK)
Abstract Slides
Presentation thumbnail
36,269 patients with chronic cardiovascular, metabolic and renal conditions: impact on clinical outcomes, medical resource use and health-related costs of deranged serum potassium levels
Doctor S. Jimenez-Marrero (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Temporal trends in cause-specific readmissions and their risk factors in heart failure patients in Sweden
Doctor X. Cui (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Estimated population prevalence of cardiac transthyretin amyloidosis in elderly men derived from incidental cardiac uptake from routine bone scans - 'we're going to need a bigger boat'.
Doctor D. Manning (Sheffield, GB)
Abstract Slides

Access the full session

Session thumbnail
Changing Epidemiology of Heart Failure

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Diastolic function and left atrial pressures
thumbnail
Congress Presentation
LV diastolic function: how to deal with challenges
thumbnail
Congress Presentation
Links between abnormal exercise parameters and diastolic dysfunction in heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources